Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unknown Timing of Lovenox Generics Complicates Sanofi-Aventis' Outlook

Executive Summary

LONDON - Sanofi-Aventis CEO Chris Viehbacher appeared uncomfortable discussing the expected timing of generic competition to Lovenox (enoxaparin) during a Feb. 10 earnings call
Advertisement

Related Content

Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Sanofi-Aventis' 2010 Guidance Remains Unchanged; Q1 Sales Up 3.9 %
NICE Accepts Fewer Side Effects In Recommending Sanofi-Aventis's Multaq
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Sanofi Expands Consumer Health Reach In China With Minsheng VMS Joint Venture
Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem

Topics

Advertisement
UsernamePublicRestriction

Register

PS051940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel